← Search & browse all drugs

gas-gangrene sera

J06AA05

Forms & Strengths

Equine polyvalent gas gangrene antitoxin injection
Varies by manufacturer; typically contains antibodies against Clostridium perfringens, C. septicum, and C. novyi

Adult Dosing

Prophylaxis: Typically 1 to 2 therapeutic doses administered IM or IV immediately following injury/exposure
Treatment: Initial dose of 1 to 5 therapeutic doses IV, repeated every 4 to 8 hours based on clinical response and toxin neutralization requirements

Pediatric Dosing

Prophylaxis: Weight-adjusted fraction of adult dose (limited data, use with extreme caution)
Treatment: Weight-adjusted fraction of adult dose administered IV, repeated based on clinical severity

Indications

Prevention and treatment of gas gangrene (clostridial myonecrosis) caused by Clostridium species such as C. perfringens, C. septicum, and C. novyi
Adjunct to surgical debridement and appropriate antimicrobial therapy (e.g., penicillin)

Mechanism of Action

Contains equine-derived neutralizing antibodies that bind to and neutralize circulating alpha-toxins and other lethal exotoxins produced by Clostridium species, preventing tissue necrosis and systemic toxicity

Contraindications

Known severe hypersensitivity or history of life-threatening anaphylaxis to equine (horse) serum proteins unless no alternative exists and desensitization protocol is performed

Adverse Reactions

Anaphylaxis and acute hypersensitivity reactions
Serum sickness (fever, rash, arthralgia, lymphadenopathy) occurring 1 to 2 weeks post-administration
Pain and inflammation at the injection site

Drug Interactions

Live vaccines: Administration of antitoxin may interfere with the immune response to live bacterial or viral vaccines; postpone vaccination if possible
Immunosuppressants: May increase risk of infection or alter immune response to the antiserum

Curated Content: Needs Vetting Before Put to Clinical Use